AI-generated summary
The authors report a prospective, open-label, single-arm study of 655 nm low-level laser therapy in men with androgenetic alopecia, comparing dermal papilla proteins from scalp biopsies before and after 24 weeks of at-home treatment. They identified 11 proteins that were up-regulated and 2 down-regulated, and linked these to processes such as lipid homeostasis and extracellular matrix. The authors state that these findings support a benefit of this therapy, though the single-arm design without a control group limits how strongly this can be interpreted.
- Who or what was studied
- Male patients with androgenetic alopecia
- Wavelengths
- 655 nm
- Limits stated in the abstract
- The study was open-label and single-arm, with no control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 655 nm
- Power
- 5 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Androgenetic alopecia, Laser, Adenosine triphosphate, Angiogenesis. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.